[
  {
    "ts": null,
    "headline": "3 major takeaways from Novo Nordisk's Q1 earnings",
    "summary": "Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings, including its global position in the GLP-1 weight-loss drug space and its partnership with CVS Health (CVS). Catch Anjalee Khemlani's full interview with Novo Nordisk CEO Lars Jørgensen. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=846e8d3f01cac5033fe19f70f6d56c21fc5eb3b6dde8c72d753ea6205a8bda0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746640800,
      "headline": "3 major takeaways from Novo Nordisk's Q1 earnings",
      "id": 134317053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings, including its global position in the GLP-1 weight-loss drug space and its partnership with CVS Health (CVS). Catch Anjalee Khemlani's full interview with Novo Nordisk CEO Lars Jørgensen. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=846e8d3f01cac5033fe19f70f6d56c21fc5eb3b6dde8c72d753ea6205a8bda0f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on CVS Health Corporation (CVS): ‘David Joyner’s Stunning Turnaround Continues’",
    "summary": "We recently published a list of Jim Cramer Reveals Trump’s Potential Secret Weapon In China Trade Talks & Discusses These 10 Stocks. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on […]",
    "url": "https://finnhub.io/api/news?id=541f7a46876beda9add1be649c9bdb397bd2841418f588f170924bec605d58a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746638471,
      "headline": "Jim Cramer on CVS Health Corporation (CVS): ‘David Joyner’s Stunning Turnaround Continues’",
      "id": 134317054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Reveals Trump’s Potential Secret Weapon In China Trade Talks & Discusses These 10 Stocks. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on […]",
      "url": "https://finnhub.io/api/news?id=541f7a46876beda9add1be649c9bdb397bd2841418f588f170924bec605d58a5"
    }
  },
  {
    "ts": null,
    "headline": "COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised",
    "summary": "COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.",
    "url": "https://finnhub.io/api/news?id=d68e24777d4e3068bd21a960abdbcce65939489792f553f1d680c790e88e0362",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746637740,
      "headline": "COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised",
      "id": 134317055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.",
      "url": "https://finnhub.io/api/news?id=d68e24777d4e3068bd21a960abdbcce65939489792f553f1d680c790e88e0362"
    }
  },
  {
    "ts": null,
    "headline": "AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down",
    "summary": "Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.",
    "url": "https://finnhub.io/api/news?id=f55926b36e431c9eada918b39a6548a49c6a50c8367be1f0458424d0e2e3aa71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746636600,
      "headline": "AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down",
      "id": 134316914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.",
      "url": "https://finnhub.io/api/news?id=f55926b36e431c9eada918b39a6548a49c6a50c8367be1f0458424d0e2e3aa71"
    }
  },
  {
    "ts": null,
    "headline": "FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y",
    "summary": "Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.",
    "url": "https://finnhub.io/api/news?id=389ec2e8a5ab9b382716dfb6ed1ec71152095e6329ef2a8203ba1bc77a744f93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746635400,
      "headline": "FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y",
      "id": 134316915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.",
      "url": "https://finnhub.io/api/news?id=389ec2e8a5ab9b382716dfb6ed1ec71152095e6329ef2a8203ba1bc77a744f93"
    }
  },
  {
    "ts": null,
    "headline": "CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y",
    "summary": "Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.",
    "url": "https://finnhub.io/api/news?id=0853ceb86f612efe73e5a708abe46234276221e6a23815b7282594162b42fac3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746635280,
      "headline": "CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y",
      "id": 134316916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.",
      "url": "https://finnhub.io/api/news?id=0853ceb86f612efe73e5a708abe46234276221e6a23815b7282594162b42fac3"
    }
  },
  {
    "ts": null,
    "headline": "MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand",
    "summary": "Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.",
    "url": "https://finnhub.io/api/news?id=3dce343c2184994a154e69c1b1ca327cce42a5795da0c3e6f464277dd39f51f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746635220,
      "headline": "MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand",
      "id": 134316917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.",
      "url": "https://finnhub.io/api/news?id=3dce343c2184994a154e69c1b1ca327cce42a5795da0c3e6f464277dd39f51f9"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing",
    "summary": "Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures came out to a total of $11.9 billion, falling in line with Wall Street estimates. Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's partnership and price goals with CVS Health (CVS), and the company's outlook on its US manufacturing position and President Trump's proposed pharmaceutical tariffs. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=fc28bb08dd04c5b7cb321dd4eed63afd116d6d82ba884138a9fa750daea07608",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746630348,
      "headline": "Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing",
      "id": 134317060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures came out to a total of $11.9 billion, falling in line with Wall Street estimates. Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's partnership and price goals with CVS Health (CVS), and the company's outlook on its US manufacturing position and President Trump's proposed pharmaceutical tariffs. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=fc28bb08dd04c5b7cb321dd4eed63afd116d6d82ba884138a9fa750daea07608"
    }
  },
  {
    "ts": null,
    "headline": "Top-Performing Stock: CVS Health Raises Outlook After Strong Earnings Beat",
    "summary": "CVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.",
    "url": "https://finnhub.io/api/news?id=ab3ba839261dd5760c083486a4172f39597dc8ad8485d0727de05eb47901f608",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746626660,
      "headline": "Top-Performing Stock: CVS Health Raises Outlook After Strong Earnings Beat",
      "id": 134317061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.",
      "url": "https://finnhub.io/api/news?id=ab3ba839261dd5760c083486a4172f39597dc8ad8485d0727de05eb47901f608"
    }
  },
  {
    "ts": null,
    "headline": "Does CVS Health (NYSE:CVS) Have A Healthy Balance Sheet?",
    "summary": "The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",
    "url": "https://finnhub.io/api/news?id=db2d18c1a8d9375304e2f74909afb9e92b271edf790d5b724945f9af1f1b88dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746619218,
      "headline": "Does CVS Health (NYSE:CVS) Have A Healthy Balance Sheet?",
      "id": 134317062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",
      "url": "https://finnhub.io/api/news?id=db2d18c1a8d9375304e2f74909afb9e92b271edf790d5b724945f9af1f1b88dc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk beats on Q1 earnings, cuts 2025 outlook",
    "summary": "Novo Nordisk reported moderate earnings, cuts 2025 outlook",
    "url": "https://finnhub.io/api/news?id=082b976c54525a87e39e43fd0a205844a737824b3738c8e1d6052a93485536e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746615011,
      "headline": "Novo Nordisk beats on Q1 earnings, cuts 2025 outlook",
      "id": 134293534,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk reported moderate earnings, cuts 2025 outlook",
      "url": "https://finnhub.io/api/news?id=082b976c54525a87e39e43fd0a205844a737824b3738c8e1d6052a93485536e2"
    }
  },
  {
    "ts": null,
    "headline": "Health insurers see signs of life in Q1",
    "summary": "Payer profits fell in 2024 as Americans, especially older ones, utilized more medical care. But efforts to resuscitate margins appear to be working for most — at least for now, according to first quarter results.",
    "url": "https://finnhub.io/api/news?id=b1175185581fa65f77c58be653513447f2714e37f7d6446ab10c6d6686c867b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746609158,
      "headline": "Health insurers see signs of life in Q1",
      "id": 134316713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Payer profits fell in 2024 as Americans, especially older ones, utilized more medical care. But efforts to resuscitate margins appear to be working for most — at least for now, according to first quarter results.",
      "url": "https://finnhub.io/api/news?id=b1175185581fa65f77c58be653513447f2714e37f7d6446ab10c6d6686c867b7"
    }
  }
]